When treated with agonist anti-4-1BB immunotherapy, TRAF2-deficient mice displayed delayed and less efficient tumor rejection, consequently carrying larger subcutaneous CT26 colorectal tumors [185]. The gene discussed is TRAF2; the disease is neoplasm.